Background: Despite the increasing use of intravenous (IV) tenecteplase (TNKase) for acute ischemic stroke (AIS), little is known about the characteristics of patients who suffer intracerebral ...

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...

Introduction: Tenecteplase (TNK) has 14-times greater specificity for fibrin and a longer half-life compared to alteplase (ALT), offering practical advantages for ease of administration and cost ...

Opens in a new tab or window Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after mechanical thrombectomy in selected stroke patients.

In patients with acute ischemic stroke due to acute intracranial occlusions of the posterior circulation, the use of ...

Jan. 30, 2025 — An artificial intelligence (AI) model designed to predict a person's biological age (age of body cells and tissues) based on electrocardiogram (ECG) data found a strong ...

Are Stroke Cases Triggering Tenecteplase TNKase Market Growth? Indeed, an escalating number of stroke cases worldwide has been identified as a critical driver behind the robust growth of the ...

Are Stroke Cases Triggering Tenecteplase TNKase Market Growth? Indeed, an escalating number of stroke cases worldwide has been identified as a critical driver behind the robust growth of the ...

The most recent acute stroke guidelines from the American Heart Association have also incorporated the use of tenecteplase in the setting where a mechanical thrombectomy is planned (4). Despite these ...

Two randomized trials have shown that the use of adjunctive intra-arterial thrombolytics does not significantly improve ...